Skip to content
Home/Companies/Biotech/ArmaGen Technologies

ArmaGen Technologies

Biotech·United States·Exited 2020·Held 6yr
Entry
2014
Hold
6yr
Exit
2020

Who owns ArmaGen Technologies?

ArmaGen Technologies is an American Biotech company, now owned by JCR Pharmaceuticals, which acquired it in 2020 from Boehringer Ingelheim Venture Fund.

Hand-verified · updated 2026-07-07

Open JSON · CC-BY
Boehringer Ingelheim Venture Fund
Investor
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund · 2010 · Evergreen

Key facts

HQUnited States
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
JCR Pharmaceuticals
Exit Year
2020

More from Boehringer Ingelheim Venture Fund

Other portfolio companies in the same fund.

ICD Therapeutics
Exited 2019
BiotechGermany
to Boehringer Ingelheim
EvlaBio
Active
BiotechGermany· 2025
ProTgen
Active
BiotechUS· 2024
Refoxy Pharmaceuticals
Refoxy Pharmaceuticals
Active
BiotechGermany· 2024
SwitchKine
Active
BiotechSwitzerland· 2024
Synthetica Pioneering
Active
BiotechChina· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns ArmaGen Technologies?

ArmaGen Technologies is now owned by JCR Pharmaceuticals, which acquired it in 2020 from Boehringer Ingelheim Venture Fund.

When did JCR Pharmaceuticals acquire ArmaGen Technologies?

JCR Pharmaceuticals acquired ArmaGen Technologies in 2020, buying from Boehringer Ingelheim Venture Fund.

Who did ArmaGen Technologies sell to?

Boehringer Ingelheim Venture Fund sold ArmaGen Technologies to JCR Pharmaceuticals in 2020 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue